Physician profile
Brian E Chavez
NPI 1215974969
$15,070.05
in general payments reported to CMS, 2019-2025
72 companies · $3,020 in 2025
The $3,020 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,606 · 2020: $1,229 · 2021: $2,255 · 2022: $1,870 · 2023: $2,723 · 2024: $2,367 · 2025: $3,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,082 · Education: $20.00 · Travel and Lodging: $8.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,081.55 |
| Education | $20.00 |
| Travel and Lodging | $8.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,712.22 | 2019-2025 | Repatha, Evenity, Tepezza |
| Lilly USA, LLC | $1,380.04 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Astrazeneca Pharmaceuticals LP | $1,085.80 | 2019-2025 | Farxiga, Saphnelo, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $973.62 | 2021-2025 | |
| Abbvie INC. | $834.03 | 2019-2025 | Synthroid, Ubrelvy |
| Mannkind Corporation | $784.59 | 2019-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $651.63 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $642.14 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $579.88 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $575.78 | 2019-2025 | |
| Corcept Therapeutics | $515.65 | 2019-2025 | Korlym |
| Cequr Corporation | $508.38 | 2022-2024 | Cequr Simplicity |
| Horizon Therapeutics Plc | $421.99 | 2021-2023 | Tepezza |
| Insulet Corporation | $420.21 | 2019-2025 | Omnipod |
| Esperion Therapeutics, INC. | $353.71 | 2021-2023 | Nexletol |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Chavez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.